Bunkerhill ECG-EF vs SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Bunkerhill ECG-EF

by Bunkerhill Health

SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION

by DIACOUSTIC MEDICAL DEVICES (PTY)

AI Verdict

Tool A focuses on detecting reduced left ventricular ejection fraction from ECGs to identify patients at risk for heart failure. Tool B, conversely, analyzes acoustic heart signals via a mobile application and electronic stethoscope to diagnose heart murmurs. While both are FDA-cleared AI tools for cardiology, their distinct input data and specific diagnostic targets make them complementary rather than direct competitors.

Choose Bunkerhill ECG-EF if…

Choose Bunkerhill ECG-EF if your primary goal is to leverage existing routine 12-lead ECG data for automated, early identification of patients at risk for heart failure due to reduced left ventricular ejection fraction. This tool is ideal for integrating into automated clinical workflows within an EHR system to efficiently screen a broad patient population for potential cardiac dysfunction.

View Bunkerhill ECG-EF →

Choose SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION if…

Choose SensiCardiac Mobi if you need an AI-powered mobile solution to assist in the real-time diagnosis and differentiation of heart murmurs during a physical examination. This application is best suited for clinicians who utilize electronic stethoscopes and require immediate decision support to distinguish between physiological and pathological heart sounds at the point of care.

View SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Bunkerhill ECG-EF	SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION
Pricing	Contact sales for pricing details.	Contact for pricing
Deployment	Cloud-native platform (Carebricks) that integrates with existing health system infrastructure like EHRs.	Hosted server environment (Linux OS) with a mobile application interface
BAA Available	Unknown	Yes AI-estimated
FDA Status	Yes AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Bunkerhill ECG-EF

Tool A emphasizes seamless integration with existing EHRs and clinical archives, supporting automated clinical workflows. This approach minimizes additional steps for clinicians within their established systems. Tool B, while offering a mobile application with good user scores, requires a separate mobile app and a user-provided electronic stethoscope, potentially adding more manual steps and device management to the clinical workflow.

Clinical Value

Bunkerhill ECG-EF

Both tools provide significant clinical value as FDA-cleared decision support. Tool A detects reduced LVEF from routine ECGs, addressing a widespread and often undiagnosed condition, offering early identification of heart failure risk at a broad scale. Tool B assists in diagnosing heart murmurs, which is valuable but may have a narrower application compared to the population-level impact of early heart failure screening from a common test.

Pricing & Value

Tie

Neither tool provides publicly available pricing information, both stating 'contact for pricing.' Without any details on their pricing models, subscription costs, or value-based agreements, it is impossible to conduct a head-to-head comparison on this dimension.

Enterprise Readiness

Bunkerhill ECG-EF

Both tools are FDA-cleared, HIPAA compliant, and offer BAAs, establishing a baseline for enterprise readiness. However, Tool A explicitly highlights 'seamless integration with EHRs and clinical archives' and is part of the broader 'Carebricks platform' designed for automating workflows across health systems. Additionally, Bunkerhill Health holds SOC 2 Type 2 and ISO 27001 certifications, indicating a more robust and mature offering for large-scale enterprise deployment.

Innovation

Bunkerhill ECG-EF

Both tools leverage AI for diagnostic assistance. Tool A's explicit mention of 'Generative AI for clinical reasoning and action' and its integration into the Carebricks platform, which processes diverse patient data for automated workflows, suggests a more advanced and comprehensive AI methodology. Detecting LVEF from routine ECGs represents a significant and complex application of AI in cardiology.

Support & Docs

SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION

Tool B has readily available user manuals and guides online, directly addressing product usage and functionality. While Tool A's website offers resources like news, case studies, and a workflow library, explicit 'support documentation' or dedicated technical support channels are not as clearly highlighted as they are for Tool B's specific product manuals.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Bunkerhill ECG-EF	SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION
Name	Bunkerhill ECG-EF	SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION
Company	BunkerHill Health	DIACOUSTIC MEDICAL DEVICES (PTY)
Description	FDA-cleared artificial intelligence algorithm that detects reduced left ventricular ejection fraction (LVEF ≤ 40%) from routine 12-lead electrocardiograms (ECGs), aiding in the early identification of patients at risk for heart failure.	FDA-cleared AI-powered mobile application that assists physicians in diagnosing heart murmurs by analyzing acoustic heart signals from an electronic stethoscope to differentiate between physiological and pathological sounds.
Key Functionality	AI algorithm to detect reduced Left Ventricular Ejection Fraction (LVEF ≤ 40%) from 12-lead ECG data.	Analyzes acoustic heart signals to distinguish between normal/physiological and pathological heart murmurs.
Categories	Cardiology AI	Cardiology AI, Clinical Decision Support & Reference
Specialties	Cardiology, Emergency Medicine, Internal Medicine	Cardiology, Internal Medicine, Pediatrics

Videos

Demos, reviews, and walkthroughs featuring Bunkerhill ECG-EF and SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How does each tool integrate into a physician's existing diagnostic workflow, considering Bunkerhill ECG-EF analyzes existing ECGs and SensiCardiac Mobi requires active auscultation with a mobile app and electronic stethoscope?

Bunkerhill ECG-EF is a software-only medical device that integrates seamlessly with EHRs and clinical archives to analyze routine 12-lead ECG data, supporting automated clinical workflows for early heart failure risk identification. SensiCardiac Mobi, conversely, is a mobile application that requires a compatible electronic stethoscope for active acquisition and analysis of acoustic heart signals, operating as decision support to complement physician assessment during auscultation.

What are the practical differences in how results from each tool are documented and accessed within the Electronic Health Record (EHR)?

Bunkerhill ECG-EF integrates seamlessly with EHRs and clinical archives, allowing its LVEF detection results to be transmitted to integrated third-party software systems like EMRs or ECG Management Systems for display and automated next steps. SensiCardiac Mobi utilizes a mobile application for data capture and display, with its algorithm running on a hosted server environment, suggesting results are primarily accessed via the mobile app and then potentially integrated into the EHR through its server environment.

What specific data is available regarding the accuracy and sensitivity of each tool in detecting reduced LVEF or differentiating heart murmurs?

Bunkerhill ECG-EF achieved a sensitivity of 82.66% and a specificity of 83.20% in identifying patients with an ejection fraction (EF) < 40%. SensiCardiac Mobi's algorithm, which is identical to its predicate device, has shown a specificity of 94% and sensitivity of 84% relative to a golden standard in a pediatric cardiac computer study.

How do the distinct diagnostic capabilities of Bunkerhill ECG-EF (LVEF from ECGs) and SensiCardiac Mobi (murmur differentiation from auscultation) align with the needs of different cardiology subspecialties or other relevant departments?

Bunkerhill ECG-EF aids in the early identification of patients at risk for heart failure from routine ECGs, making it suitable for Cardiology, Emergency Medicine, and Internal Medicine. SensiCardiac Mobi assists physicians in diagnosing heart murmurs by analyzing acoustic heart signals to differentiate between physiological and pathological sounds, aligning with the needs of Cardiology, Internal Medicine, and Pediatrics.

What is the expected learning curve for physicians and clinical staff to effectively use each tool, and how quickly can a practice expect to see clinical value?

Bunkerhill ECG-EF, as a software-only medical device that analyzes existing ECG data and supports automated clinical workflows, may offer a relatively low learning curve for physicians and rapid time-to-value by streamlining processes. SensiCardiac Mobi requires the use of a mobile application and a user-provided compatible electronic stethoscope, which may involve a learning curve for operating the mobile interface and integrating the physical device into the examination process, though its usability has been noted as improved over a PC version.

What audit-trail capabilities does each tool offer to track how AI-generated insights are used and integrated into patient care decisions?

The provided descriptions for Bunkerhill ECG-EF and SensiCardiac Mobi do not explicitly detail specific audit-trail features or capabilities for tracking the utilization of their AI-generated insights in clinical decision-making within the given information.